This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analyst Goes to Sweden, Returns Home Predicting Vertex CF Drug Failure

By: Adam Feuerstein | 06/16/14 - 07:01 AM EDT

Bernstein analyst Geoff Porges hung out with doctors and cystic fibrosis experts at the just-concluded European Cystic Fibrosis Society conference in Sweden and returned home even more bearish on Vertex Pharmaceuticals (VRTX). In a research note Monday, Porges lays out reasons why the super-important combination studies of Kalydeco and VX-809 -- TRAFFIC and TRANPORT -- are more likely to fail.

Porges:

Our conclusion from the many conversations with basic scientists, clinicians and investigators is the same as the one that led to our downgrade of Vertex's stock 7 months ago. The probability of failure in this trial is high, and is underappreciated by the investment community. More than ever there seems to be a disconnect between the assumptions and expectations of the investor community and that of the medical community involved in the trial.

Healthcare investors, not to mention the cystic fibrosis community, are waiting anxiously for Vertex to disclose the results from the TRAFFIC and TRANSPORT studies. Wall Street sentiment has been cautious, but generally speaking, more inclined to believe the Kalydeco VX-809 studies will be positive, based on investor surveys. I've explained the bull case for TRAFFIC and TRANSPORT already

A good portion of Porges' Monday note highlights some basic science, or mechanistic, problems for VX-809, suggesting the drug may not correct protein mis-folding well enough. He believes Wall Street may be under-estimating the complexity of treating cystic fibrosis patients homozygous for the F508del mutation.

Porges:


As we sat through the basic science presentations at the conference, and then talked to many of the same scientists presenting this research, our conviction about the under-appreciated complexity of correction was increased. Much of the justification for clinical trial decisions and designs in CF came from cell culture systems, which then transitioned to relatively small "proof of concept" clinical trials. It appears that the success of Kalydeco's transition from cell culture to small trials, then to larger trials and approval, was so positive, that the sponsor (Vertex) and the partner (CF Foundation) and the CF clinical research community may have been lulled into a sense of overconfidence about the ability to make this speedy transition again with the much more complex two-drug combination. However, fully functioning humans, and diseases, tend to have much more complexity than isolated cells and even organoids, and some experts we met in Sweden suggested that this complexity may have been under-appreciated in the rush to pivotal trials to expand the treatable patient population for Vertex's drugs.



Porges is also concerned about the lack of positive, anecdotal reports from patients enrolled in the TRAFFIC and TRANSPORT studies, and says CF experts were surprisingly cautious when speaking about the outlook for the studies at this weekend's meeting. In terms of timing, Porges believes Vertex is more likely to announce TRAFFIC and TRANSPORT results in mid to late July, in part because Vertex is taking extra caution in validating and analyzing the trials' data. 

"Overall this meeting reinforced our cautious view about the probability of success for what is looming as not just a major binary event for Vertex, but as a key event for investor sentiment about the whole biotech sector," Porges concludes.

The Vertex bear has spoken. 














Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Other Posts In Adam's Biotech Beat:

Get More Investment Ideas:

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs